Pathology and Chronic Disease Management
With changing healthcare dynamics such as the increasing average age of patients, a less healthy society, increased demand for tests and decreased funding, many laboratories are feeling the impact. One area where this impact is highlighted relates to the use of pathology to control chronic disease. A topic covered incredibly well by Dr Beverley Rowbotham, Director of Haematology at Sullivan Nicolaides Pathology (Brisbane) at the National Pathology Forum Sydney in 2013.
Deborah Steele, Product Manager for the Health IT product suite at Sysmex, outlines the key points from this presentation.
The burden of chronic disease is increasing rapidly in our populations. This in turn drives an increase in pathology testing. Are more tests being ordered because there is not enough information about how test results should best be interpreted? Can clinicians pick a true change in test results, and therefore clinically significant patterns? The answer to these questions indicated information available at the point of test ordering is insufficient and there are gaps in the interpretation of patient lab reports.
Using HBA1C as an example, on average six monthly testing is unnecessary (Aronsen et al, NHS Diabetes). Providing better guidelines on intervals between testing2 will facilitate a change in the trend of over-ordering of lab tests.
How can labs provide better guidance; i.e. how often are tests needed? Can we guide testing intervals? What is a meaningful change in a test results?
How can value be added for patients, so that the pathology spend is measured in terms of patient care. Current health funding remains focused on treatment, the cost of hospitalisation dominates the health spend and pathology is often referred to as a “cost centre”.
Dr Rowbotham proposed that the laboratory service be utilised as a risk management strategy for health care outcomes by implementing the following initiatives:
These initiatives together contribute to a patient-centric care model. Pathology testing is a valuable component of chronic disease management and healthcare needs to expand on the traditional methods of diagnosis, treatment, compliance monitoring and prognosis to novel and perhaps “disruptive” approaches.
In summary, the message from the presentation challenged laboratories to meet increasing demands on lab testing in parallel with the increase in patients with chronic disease:
Written by:Deborah Steele
Deborah Steele is the Health IT Product Manager at Sysmex and oversees the direction of the Sysmex IT product suite. Deborah’s experience includes 9 years as a Medical Laboratory Scientist working in both New Zealand and London, pharmaceutical industry product management, plus 12 years’ in product specialist and marketing roles at Sysmex.